Enhancer of anti-tumor effect of anti-cancer agent

• US 9,889,155 B2
• Filed: 02/20/2015
• Issued: 02/13/2018
• Est. Priority Date: 02/20/2014
• Status: Active Grant

• Current Assignee: Hirofumi Yamamoto, Masaki Mori
• Original Assignee: Hirofumi Yamamoto, Masaki Mori
• Inventors: Yamamoto, Hirofumi, Mori, Masaki, Doki, Yuichiro, Wu, Xin
• Primary Examiner(s): PACKARD, BENJAMIN J
• Application Number:
  US15/119,862
• Publication Number:
  US 20170128487A1
• Time in Patent Office: 1,089 Days
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/337 having four-membered rings, e.g. taxol
• CPC Class Codes: A61K 31/513 having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
• CPC Class Codes: A61K 31/555 containing heavy metals, e.g. hemin, hematin, melarsoprol
• CPC Class Codes: A61K 31/704 attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin digitoxin A61K31/7048
• CPC Class Codes: A61K 33/06 Aluminium, calcium or magnesium; Compounds thereof , e.g. clay
• CPC Class Codes: A61K 33/24 Heavy metals; Compounds thereof
• CPC Class Codes: A61K 33/243 Platinum; Compounds thereof
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

An object of the present invention is to provide an agent that potentiates the antitumor effect of an anticancer agent by allowing efficient accumulation of the anticancer agent in tumor tissue. The administration of carbonate apatite with the anticancer agent allows efficient accumulation of the anticancer agent in the tumor tissue to dramatically potentiate the antitumor effect of the anticancer agent.

Claims

1. A method for treating cancer comprising the step of administering effective amounts of carbonate apatite particles and an anticancer agent to a cancer patient, wherein the anticancer agent is not contained in the carbonate apatite particles and wherein the carbonate apatite particles reduce interstitial fluid pressure in a tumor tissue in the cancer patient.

2. The method according to claim 1, wherein the carbonate apatite is in the form of nanoparticles with an average particle size of 50 nm or less.

3. The method according to claim 1, wherein the anticancer agent is at least one selected from the group consisting of antimetabolites, platinum agents, microtubule inhibitors, and anticancer antibiotics.

4. The method according to claim 1, wherein the anticancer agent is at least one selected from the group consisting of 5-fluorouracil, cisplatin, oxaliplatin, docetaxel, and doxorubicin hydrochloride.

5. The method according to claim 1, further comprising albumin.

6. A method for reducing interstitial fluid pressure in tumor tissue comprising the step of administering an effective amount of carbonate apatite particles to a cancer patient, wherein an anticancer agent is not contained in the carbonate apatite particles and wherein the carbonate apatite particles reduce interstitial fluid pressure in a tumor tissue in the cancer patient.

7. A method for enhancing accumulation of a drug in tumor tissue comprising the step of administering effective amounts of carbonate apatite and a drug to a cancer patient, wherein the drug is not contained in the carbonate apatite particles and wherein the carbonate apatite particles reduce interstitial fluid pressure in a tumor tissue in the cancer patient.